The relationship of serum visfatin levels with clinical parameters, flow-mediated dilation, and carotid intima-media thickness in patients with ankylosing spondylitis

Basit Öğe Kaydı
dc.contributor.authorAydogan Baykara, Rabia
dc.contributor.authorKucuk, Adem
dc.contributor.authorTuzcu, Ayca
dc.contributor.authorTuzcu, Goksel
dc.contributor.authorCure, Erkan
dc.contributor.authorUslu, Ali Ugur
dc.contributor.authorOmma, Ahmet
dc.date.accessioned2024-02-23T14:37:25Z
dc.date.available2024-02-23T14:37:25Z
dc.date.issued2021
dc.departmentNEÜen_US
dc.description.abstractBackground/aim: Atherosclerotic heart diseases can occur at an early age in patients with ankylosing spondylitis (AS). Flow-mediated dilation (FMD) and carotid intima-media thickness (cIMT) values are reliable markers for early detection of subclinical atherosclerosis in patients with AS. We aimed to investigate the relationship between visfatin levels and indirect markers of subclinical atherosclerosis and endothelial dysfunction in patients with AS. Materials and methods: Forty-two patients diagnosed with AS and 42 age, sex, and body mass index (BMI)-matched controls were included in the study. Visfatin levels, FMD, and cIMT were measured using appropriate methods. Results: Visfatin levels of the patients were significantly higher than controls (p < 0.001). FMD values in patients with AS were significantly lower (p = 0.007) whereas cIMT were significantly higher than the controls (p = 0.003). There was a negative relationship between FMD with visfatin levels (p = 0.004), BASDAI (p = 0.010), and BASFI (p = 0.007). There was a positive relationship between cIMT with visfatin (p = 0.005), BASDAI (p < 0.001), and BASFI (p < 0.001). There was a positive relationship between visfatin with BASDAI (p < 0.001), and BASFI (p < 0.001). Conclusion: Visfatin levels are increased and associated with impaired FMD and increased cIMT in patients with AS. Increased visfatin levels may be associated with subclinical atherosclerosis in AS.en_US
dc.identifier.doi10.3906/sag-2012-351
dc.identifier.endpage1874en_US
dc.identifier.issn1300-0144
dc.identifier.issn1303-6165
dc.identifier.issue4en_US
dc.identifier.pmid33754654en_US
dc.identifier.scopus2-s2.0-85114217367en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1865en_US
dc.identifier.urihttps://doi.org/10.3906/sag-2012-351
dc.identifier.urihttps://hdl.handle.net/20.500.12452/16095
dc.identifier.volume51en_US
dc.identifier.wosWOS:000691544700035en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTubitak Scientific & Technological Research Council Turkeyen_US
dc.relation.ispartofTurkish Journal Of Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectVisfatinen_US
dc.subjectAnkylosing Spondylitisen_US
dc.subjectFlow-Mediated Dilationen_US
dc.subjectCarotid Intima-Media Thicknessen_US
dc.subjectSubclinical Atherosclerosisen_US
dc.titleThe relationship of serum visfatin levels with clinical parameters, flow-mediated dilation, and carotid intima-media thickness in patients with ankylosing spondylitisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu